Item 11. Other Business Chair: excellencies, distinguished delegates, ladies and gentlemen. We will now resume from where we had closed the session before lunch by adopting L10 and we will now proceed to the consideration of L6 rev. 1 as amended by L10. Is the commission ready to adopt L6 rev 1 as amended by …
China
Plenary – Thursday morning session
Item 6. Follow-up to the implementation at the national, regional and international levels of all commitments, as reflected in the Ministerial Declaration of 2019, to address and counter the world drug problem (continued) United States: The US takes the floor to address statements made yesterday regarding the mandate of the INCB which we do not …
Committee of the Whole – Thursday morning session
L6 Strengthening the global drug control framework: a path to effective implementation E/CN.7/2025/L.6 Colombia: we updated the document to reflect all recent agreements from last night, we are still working hard with delegations to find consensus across the document Chair: We start with deliberating the title, the floor is open. Sudan: it was only …
Plenary — Wednesday afternoon session
Youth Forum: Your excellencies, distinguished delegates, ladies and gentleman. From 25 countries we gather as a unified voice to address the issue of substance use in our communities. This is not a new challenge and has been tackled over the past decades. Everyday there are new substances threatening individuals and society as a whole. It …
Committee of the Whole – Wednesday morning session
L.5. Safety of officers in dismantling illicit synthetic opioid laboratories OP 2 (c) (…) China: We would like to delete the wording from ‘exposure’ to ‘chemicals’. United States: WE would like to remain faithful to the intention of sponsors, which is in line with our policy. This resolution is for all member states but some …
Plenary — Wednesday morning session
Item 5. Implementation of the international drug control treaties (continued) (a) Changes in the scope of control of substances Chair: First, Commission will consider recommendations of WHO on 4 substances, namely: (a) Whether or not it wishes to include N-pyrrolidino protonitazene in Schedule I of the 1961 Convention as amended; (b) Whether or not it …